Beyond EGFR and ALK inhibition: Unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer. Issue 5 (May 2015)

• Record Type: Journal Article
• Authors: Califano, Raffaele; Abidin, Aidalena; Tariq, Noor-ul-Ain; Economopoulou, Panagiota; Metro, Giulio; Mountzios, Giannis
• Is Part Of: Cancer treatment reviews. Volume 41:Issue 5(2015)
• Page Start: 401
• Page End: 411
• Publication Date: 2015-05
• Subjects: Cancer -- Periodicals; Cancer -- Treatment -- Periodicals; Neoplasms -- therapy -- Periodicals; Cancer -- Périodiques; Cancer -- Traitement -- Périodiques; Cancer -- Treatment; Electronic journals; Periodicals; 616.99406
• DOI: 10.1016/j.ctrv.2015.03.009
• Languages: English
• ISSNs: 0305-7372

Abstract

<abstract xml:lang="en" abstract-type="author-highlights" id="ab005"> <title id="st005">Highlights</title> <sec> <p id="sp0005"> <list id="l0005"> <list-item id="o0005"> <label></label> <p id="p0005">Novel molecular events that characterize NSCLC transformation may represent oncogenic drivers amenable to targeted therapy.</p> </list-item> <list-item id="o0010"> <label></label> <p id="p0010">Drivers beyond EGFR and ALK inhibition have emerged as novel molecular targets with potential therapeutic implications.</p> </list-item> <list-item id="o0015"> <label></label> <p id="p0015">These targets include genetic alterations in the genes <italic>KRAS</italic>, <italic>BRAF</italic>, <italic>HER2</italic>, <italic>PI3KCA</italic>, <italic>DDR2</italic>, <italic>ROS1</italic>, <italic>RET</italic>, <italic>MET</italic>, <italic>HER2</italic> and <italic>FGFR1</italic>.</p> </list-item> <list-item id="o0020"> <label></label> <p id="p0020">A number of molecules that target the aforementioned genetic alterations are in early phase of clinical development.</p> </list-item> </list> </p> </sec> </abstract>